ADRB2 and neoplasm: Thus, we observed an association between the increased immunoreactivity of beta 2 adrenergic receptors and the age of patients younger than 60 years (37 patients—62.71%, Odds ratio 3.134, 95% CI 1.475 to 6.606, p = 0.0021), tumors moderately and respectively poorly differentiated (tumor grading G2 and G2 52 patients—54.17%, Odds ratio 3.208, 95% CI 1.235 to 8.034, p = 0.0157) but there was also a lack of response to first-line chemotherapy (46 patients—54.76%, Odds ratio 2.328, 95% CI 1.059 to 5.217, p = 0.0450).